PeptiDream And Two More Japanese Exchange Growth Companies With High Insider Ownership
Reviewed by Simply Wall St
Amid a backdrop of fluctuating market conditions, Japan's stock markets experienced negative returns last week, with uncertainties around the Bank of Japan’s monetary policy affecting investor sentiment. In such an environment, companies like PeptiDream that boast high insider ownership may offer investors a sense of stability and alignment of interests between shareholders and management.
Top 10 Growth Companies With High Insider Ownership In Japan
Name | Insider Ownership | Earnings Growth |
SHIFT (TSE:3697) | 35.4% | 26.8% |
Kanamic NetworkLTD (TSE:3939) | 25% | 28.9% |
Hottolink (TSE:3680) | 27% | 57.3% |
Medley (TSE:4480) | 34% | 28.7% |
Micronics Japan (TSE:6871) | 15.3% | 39.8% |
Kasumigaseki CapitalLtd (TSE:3498) | 34.8% | 44.6% |
ExaWizards (TSE:4259) | 24.8% | 91.1% |
Soiken Holdings (TSE:2385) | 19.8% | 118.4% |
AeroEdge (TSE:7409) | 10.7% | 28.5% |
freee K.K (TSE:4478) | 24% | 81% |
Below we spotlight a couple of our favorites from our exclusive screener.
PeptiDream (TSE:4587)
Simply Wall St Growth Rating: ★★★★★☆
Overview: PeptiDream Inc. is a biopharmaceutical company focused on the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics, with a market capitalization of approximately ¥321.43 billion.
Operations: The company primarily generates revenue through its biopharmaceutical development activities, focusing on novel peptides and molecular therapeutics.
Insider Ownership: 26.1%
PeptiDream, a Japanese biotech firm, recently enhanced its financial outlook for 2024, doubling its operating profit forecast to JPY 20.10 billion and nearly doubling expected net profit to JPY 14.00 billion following strategic expansions with Novartis. This includes an upfront payment of US$180 million and potential milestones up to US$2.71 billion, emphasizing PeptiDream's robust growth trajectory in peptide-based therapeutics. Despite high market volatility and lower current profit margins compared to last year, the company's innovative edge in drug development is clear with promising clinical studies underway for renal cell carcinoma diagnostics using its proprietary technology.
- Take a closer look at PeptiDream's potential here in our earnings growth report.
- The valuation report we've compiled suggests that PeptiDream's current price could be inflated.
Rakuten Group (TSE:4755)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Rakuten Group, Inc. operates in e-commerce, fintech, digital content, and communications sectors serving a diverse global clientele with a market capitalization of approximately ¥1.83 trillion.
Operations: The company generates revenue through its operations in e-commerce, fintech, digital content, and communications.
Insider Ownership: 17.3%
Rakuten Group is positioned for notable growth with forecasted revenue increases outpacing the Japanese market. Despite trading significantly below its perceived fair value, Rakuten anticipates becoming profitable within three years, aligning with a strategy of robust operational expansion as evidenced by a recent $1.99 billion bond issuance. Challenges remain, including modest projected return on equity and abandoning plans to list its securities unit, reflecting a cautious approach amid broader financial strategies.
- Click here and access our complete growth analysis report to understand the dynamics of Rakuten Group.
- The valuation report we've compiled suggests that Rakuten Group's current price could be quite moderate.
BayCurrent Consulting (TSE:6532)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: BayCurrent Consulting, Inc., a company based in Japan, offers consulting services and has a market capitalization of approximately ¥495.07 billion.
Operations: The firm generates its revenue primarily through consulting services in Japan.
Insider Ownership: 13.9%
BayCurrent Consulting, with its substantial insider ownership, is trading at 59.1% below its estimated fair value, indicating potential undervaluation. The company's earnings and revenue are expected to grow at 18.41% and 18.3% per year respectively, outpacing the Japanese market averages of 8.9% for earnings and 4.2% for revenue growth. Despite this promising outlook, the share price has shown high volatility recently. Additionally, a recent share buyback program for ¥3.60 billion suggests a focus on shareholder value and capital efficiency.
- Click here to discover the nuances of BayCurrent Consulting with our detailed analytical future growth report.
- The analysis detailed in our BayCurrent Consulting valuation report hints at an deflated share price compared to its estimated value.
Turning Ideas Into Actions
- Dive into all 99 of the Fast Growing Japanese Companies With High Insider Ownership we have identified here.
- Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
- Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.
Want To Explore Some Alternatives?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About TSE:4587
PeptiDream
A biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics.
Undervalued with solid track record.